Literature DB >> 30239618

Evidence for peri-ictal blood-brain barrier dysfunction in patients with epilepsy.

Theodor Rüber1, Bastian David1, Guido Lüchters2, Robert D Nass1, Alon Friedman3,4, Rainer Surges1,5, Tony Stöcker6, Bernd Weber1, Ralf Deichmann7, Gottfried Schlaug8, Elke Hattingen9, Christian E Elger1.   

Abstract

Epilepsy has been associated with a dysfunction of the blood-brain barrier. While there is ample evidence that a dysfunction of the blood-brain barrier contributes to epileptogenesis, blood-brain barrier dysfunction as a consequence of single epileptic seizures has not been systematically investigated. We hypothesized that blood-brain barrier dysfunction is temporally and anatomically associated with epileptic seizures in patients and used a newly-established quantitative MRI protocol to test our hypothesis. Twenty-three patients with epilepsy undergoing inpatient monitoring as part of their presurgical evaluation were included in this study (10 females, mean age ± standard deviation: 28.78 ± 8.45). For each patient, we acquired quantitative T1 relaxation time maps (qT1) after both ictal and interictal injection of gadolinium-based contrast agent. The postictal enhancement of contrast agent was quantified by subtracting postictal qT1 from interictal qT1 and the resulting ΔqT1 was used as a surrogate imaging marker of peri-ictal blood-brain barrier dysfunction. Additionally, the serum concentrations of MMP9 and S100, both considered biomarkers of blood-brain barrier dysfunction, were assessed in serum samples obtained prior to and after the index seizure. Fifteen patients exhibited secondarily generalized tonic-clonic seizures and eight patients exhibited focal seizures at ictal injection of contrast agent. By comparing ΔqT1 of the generalized tonic-clonic seizures and focal seizures groups, the anatomical association between ictal epileptic activity and postictal enhancement of contrast agent could be probed. The generalized tonic-clonic seizures group showed significantly higher ΔqT1 in the whole brain as compared to the focal seizures group. Specific analysis of scans acquired later than 3 h after the onset of the seizure revealed higher ΔqT1 in the generalized tonic-clonic seizures group as compared to the focal seizures group, which was strictly lateralized to the hemisphere of seizure onset. Both MMP9 and S100 showed a significantly increased postictal concentration. The current study provides evidence for the occurrence of a blood-brain barrier dysfunction, which is temporally and anatomically associated with epileptic seizures. qT1 after ictal contrast agent injection is rendered as valuable imaging marker of seizure-associated blood-brain barrier dysfunction and may be measured hours after the seizure. The observation of the strong anatomical association of peri-ictal blood-brain barrier dysfunction may spark the development of new functional imaging modalities for the post hoc visualization of brain areas affected by the seizure.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30239618     DOI: 10.1093/brain/awy242

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  29 in total

1.  Postictal serotonin levels are associated with peri-ictal apnea.

Authors:  Arun Murugesan; M R Sandhya Rani; Laura Vilella; Nuria Lacuey; Johnson P Hampson; Carl L Faingold; Daniel Friedman; Orrin Devinsky; Rup K Sainju; Stephan Schuele; Beate Diehl; Maromi Nei; Ronald M Harper; Lisa M Bateman; George Richerson; Samden D Lhatoo
Journal:  Neurology       Date:  2019-09-04       Impact factor: 9.910

2.  A case of focal cortical dysplasia type Ib atypically showing reversible intensity changes on magnetic resonance imaging which could be affected by epileptic discharge activity.

Authors:  Naoto Kuroda; Ayataka Fujimoto; Hideo Enoki; Yoshifumi Arai; Tohru Okanishi
Journal:  Childs Nerv Syst       Date:  2019-02-27       Impact factor: 1.475

3.  Epilepsy and Alterations of the Blood-Brain Barrier: Cause or Consequence of Epileptic Seizures or Both?

Authors:  Wolfgang Löscher
Journal:  Handb Exp Pharmacol       Date:  2022

Review 4.  The Blood-Brain Barrier: Much More Than a Selective Access to the Brain.

Authors:  Fredy Sanchez-Cano; Luisa C Hernández-Kelly; Arturo Ortega
Journal:  Neurotox Res       Date:  2021-10-22       Impact factor: 3.911

Review 5.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

6.  Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus.

Authors:  Maximilian Lenz; Marina Ben Shimon; Felix Benninger; Miri Y Neufeld; Efrat Shavit-Stein; Andreas Vlachos; Nicola Maggio
Journal:  J Mol Med (Berl)       Date:  2019-10-31       Impact factor: 4.599

7.  Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy.

Authors:  Cristina R Reschke; Luiz F A Silva; Vamshidhar R Vangoor; Massimo Rosso; Bastian David; Brenton L Cavanagh; Niamh M C Connolly; Gary P Brennan; Amaya Sanz-Rodriguez; Catherine Mooney; Aasia Batool; Chris Greene; Marian Brennan; Ronan M Conroy; Theodor Rüber; Jochen H M Prehn; Matthew Campbell; R Jeroen Pasterkamp; David C Henshall
Journal:  Mol Ther       Date:  2021-02-18       Impact factor: 12.910

8.  Identification of significant immune-related genes for epilepsy via bioinformatics analysis.

Authors:  Xiaodan Luo; Tao Xiang; Hongmi Huang; Lin Ye; Yifei Huang; Yuan Wu
Journal:  Ann Transl Med       Date:  2021-07

9.  Vascular Expression of Permeability-Resistant Occludin Mutant Preserves Visual Function in Diabetes.

Authors:  Andreia Goncalves; Alyssa Dreffs; Cheng-Mao Lin; Sarah Sheskey; Natalie Hudson; Jason Keil; Matthew Campbell; David A Antonetti
Journal:  Diabetes       Date:  2021-04-21       Impact factor: 9.337

Review 10.  MicroRNAs as regulators of brain function and targets for treatment of epilepsy.

Authors:  Gary P Brennan; David C Henshall
Journal:  Nat Rev Neurol       Date:  2020-06-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.